Jim Hoffman: Exploring Extracorporeal Strategies to Target NETs in Cardiovascular Disease
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared Apherese ForschungsInstitut – AFI’s post on LinkedIn, adding:
”Lp(a) does not act alone to help facilitate potentially life-threatening occlusive atheromas. Other factors, such as NETosis dysfunction and poor NET clearance, are likely at play, increasing the risk of CVD, heart failure, MI, and strokes.
Here are two other extracorporeal methods that target elevated extracellular chromatin/NETs that I believe should be trialed for potentially reversing diet and drug-refractory atherogenesis. They are simpler to perform and could be more efficacious than H.E.L.P. apheresis and other extracorporeal methods of lipid lowering.
A Novel Role for Lipoprotein(a) in Potentiating Neutrophil Extracellular Trap Formation.
More research linking NETosis dysfunction to atherosclerosis progression and atheroma development can be found
Quoting Apherese ForschungsInstitut – AFI’s post:
”Elevated Lipoprotein(a) is a major, genetically determined driver of cardiovascular risk, yet it remains largely untouched by traditional lifestyle changes and statins.
A recent review in the European Heart Journal titled ‘Lipoprotein(a)-lowering therapies: a promising future’ highlights the evolving landscape of treatment.
At the Apherese Forschungsinstitut, we closely follow these developments. Phase III trials of RNA-based therapies specifically targeting Lp(a) are currently underway. Until these new drugs reach the market and prove long-term outcomes, Lipoprotein Apheresis continues to be the life-saving ‘gold standard’ for patients with extreme Lp(a) elevation and progressive ASCVD.
In the current therapeutic landscape, Lipoprotein Apheresis remains the only established and highly effective method to significantly reduce Lp(a) levels and mitigate cardiovascular events in high-risk patients.”
Title: Lipoprotein(a)-lowering therapies: a promising future
Authors: Jingwen Zhang, Ann Marie Navar, Lale Tokgozoglu
Read the Full Article on Apherese ForschungsInstitut – AFI
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation